2023 年 APEC 優良查驗登記管理(GRM)國際研討會成果報告

一、前言

為增進 APEC 亞太區域法規協和,同時提升醫藥品查驗登記管理品質和效率,衛生福利部食品藥物管理署(以下簡稱食藥署)於 112 年 9 月 6 至 9 月 8 日舉辦為期 3 天之「2023 APEC 優良查驗登記管理國際研討會(2023 APEC Good Registration Management CoE Workshop)」。

APEC 是我國正式參與的多邊官方經濟合作論壇,食藥署長期參與 APEC RHSC 活動,積極推動倡議區域法規協和,自 2016 年至今每年藉由法規培訓活動培訓 70~110 位不等之 APEC 經濟體種子師資,藉此落實及推廣亞太區域優良查驗登記管理(GRM)理念,提升整體醫藥品審查和送件效率。



二、研討會議程、邀請講師及參與學員

由於 COVID-19 疫情影響,2021-2022 年之優良查驗登記管理(GRM)法規科學卓越中心(CoE)國際研討會皆以視訊方式辦理,2023 年 APEC 優良查驗登記管理國際研討會於 COVID-19 疫情後首度恢復實體辦理。研討會議程內容以 GRM核心課綱(優良審查及優良送審規範)為主要培訓議題內容,議程請詳閱下頁研討會議程。

邀請美國 FDA、歐盟 EMA、日本 PMDA、美國南加州大學(USC)法規科學國際中心 (International Center for Regulatory Science, University of Southern California)、財團法人醫藥品查驗中心(CDE)及中華民國開發性製藥研究協會 (IRPMA)等產官學專家共 21 位擔任講師,分享優良查驗登記管理規範和實務經驗。

本次研討會共有 81 位學員(22 名審查人員及 59 名業界人士)完成此次推廣 GRM 理念的教育訓練,分別來自 5 個 APEC 經濟體(馬來西亞、菲律賓、新加坡、泰國及我國)及 1 個非 APEC 經濟體(波札那)之產官學界醫藥品法規人員。

2023 APEC Good Registration Management (GRM) CoE Workshop Agenda

September 6 th 2023		
Time	Topics	Affiliation/Economy
09:00-09:20	Opening Remarks	Shou-Mei Wu (吳秀梅署長) Director General, Taiwan Food and Drug Administration (TFDA) Ayumi Endo Office Director, Office of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, (PMDA) Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan
09:20-09:35	GROUP PHOTO	
Keynote Speech 1 【Moderator】Yi-Chu Lin(林意筑專門委員), Senior Specialist, Division of Medicinal Product, TFDA		
09:35-10:15	Good Review Practice and Regulatory Convergence in Accepting Global Clinical Data for Regulatory Approval	Herng-Der Chern (陳恆德醫 師) Standing Director, Taiwan Society of Regulatory Affairs for Medical Products

Г		T		
10:15-10:25	Q&A			
10:25-10:40	10:25-10:40 COFFEE BREAK			
Keynote Spe	ech 2			
[Moderato	r】Yi-Chu Lin(林意筑專門委員)	, Senior Specialist, Division of		
Medicinal Pro	oduct, TFDA			
	Aaron Sosa Mejia			
		· ·		
	Assessment of Global Clinical	Medical Oncologist, Chief		
10:40-11:20	Data for Drug Approval in	Medical Officer, Danish		
	Europe	Medicines Agency (DKMA), and		
		Alternate CHMP member for		
		Denmark, European Medicines		
11:20-11:30	Q&A	Agency (EMA)		
Session 1: In	troduction of GRM			
[Moderato	r】Mei-Chen Huang(黃玫甄簡任	技正), Senior Technical		
Specialist, Di	vision of Medicinal Product, TFD	A		
		Kuo-Teng Hung (洪國登科長)		
11:40-12:00	- Concept of GRM	Section Chief, Division of		
	- Objective of the training	Medicinal Product, TFDA		
12:00-13:00	LUNCH	,		
12.00 13.00	Letteri	A LIVEZ		
Session 2: M	anaging and Conducting the Rev	view		
[Moderato	r】Mei-Chen Huang(黃玫甄簡任	÷技正), Senior Technical		
Specialist, Di	vision of Medicinal Product, TFD	A		
	An introductory overview of	Yueh-Tung Tsai (蔡岳橦技正)		
13:00-13:40	Managing and Conducting	Technical Specialist, Division of		
	the Review	Medicinal Product, TFDA		
		Kanae Ohara		
	Clabal CP 1 LD 4	Coordinator, Office of Asia		
12.40 14.20	Global Clinical Data	Training Center for		
13:40-14:20	Evaluation for Drug	Pharmaceuticals and Medical		
	Approval in Japan	Devices Regulatory Affairs,		
		PMDA		
		•		

14:20-15:20	Current Practices for Managing and Conducting the Review of New Drug Applications in 3 Economies	Representatives from 3 economies
15:20-15:35	Panel Discussion	Yueh-Tung Tsai (蔡岳樟技正) Technical Specialist, Division of Medicinal Product, TFDA Ayumi Endo Office Director Office of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs, PMDA Representatives from 3 economies
15:35-15:50	COFFEE BREAK	
Session 3: Regulatory Competency Framework 【Moderator】Ming-Mei Wu(吳明美副組長), Deputy Director, Division of Medicinal Product, TFDA Regulatory Competency 15:50-16:20 Framework: A Tool to Help International Contentor		
	Planning Professional Development and Training	International Center for Regulatory Science, University of Southern California (USC)
16:20-16:50	Rolling Out the GRM Training Program in Each Economy: Trainer's Manual	Hiroko Kawaguchi Prin. Scientist, MSD. K. K RA-EWG APAC (Japan)
16:50-17:00	Q&A	

September 7 th 2023			
Time	Topics	Affiliation/Economy	
Session 4: Planning of Application [Moderator] Rosa Fu, Director, Regulatory Affairs, Eli Lilly and Company(Taiwan), IRPMA			
08:30-08:35 08:35-09:25	Ice Breaker Introductory Lectures - Planning of New Drug application - Planning of Generic Drug applications	【Speaker】 Finny Liu APAC Regional Regulatory Policy Lead, Roche Singapore Jocelyn Lee Director of Regulatory Affair,	
09:25-10:15	Group Discussion Case Studies: New Drugs & Generic Drugs	Senhwa Biosciences [Facilitator] IRPMA & TFDA/CDE Members	
10:15-10:30	COFFEE BREAK	Wiemoers	
10:30-11:20	Group Presentation Case Studies: New Drugs & Generic Drugs		
Session 5-1: Preparation of Application Dossier / Practice: How to Prepare Application Dossier [Moderator] Yukiko Noguchi, Associated Director, Regulatory Affairs, Astellas Pharma Inc. RA-EWG APAC (Japan)			
11:30-11:35	<u>Ice Breaker</u>	Yukiko Noguchi Associated Director, Regulatory Affairs, Astellas Pharma Inc. RA-EWG APAC (Japan)	
11:35-12:15	Lectures - Standard process of application dossier preparation	Kumiko Hikida Manager, Global Regulatory Affairs Department, Mitsubishi Tanabe Pharma Corporation,	

		JAPAN, RA-EWG APAC (Japan)
	- Support tools	Masaaki Kanno SP Team Lead Overseas Regulatory Office Regulatory Affairs Department Otsuka Pharmaceutical Co., Ltd.
12:15-13:10		LUNCH TIME

Session 5-2: Preparation of Application Dossier / Practice: How to Prepare Application Dossier

[Moderator] Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan

13:10-14:00	Group Discussion Practice: How to prepare application dossier	[Moderator] Shinji Hatakeyama Leader, Regulations and
14:00-14:50	Group Presentation Practice: How to prepare application dossier	Approvals Expert Working Group (RA-EWG), APAC, and Director, Japan/Asia Regulatory & Asia Clinical Operations Department, Medicine Development Center, Eisai Co., Ltd, Japan 【Facilitator】 IRPMA&TFDA/CDE Members
14:50-15:00	COFFEE BREAK	

Session 6: Communications

【Moderator】Min Chen(李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research (CDER), US FDA

15:00-15:20	Lectures - Good communications: Fundamentals from Regulatory Perspectives	Min Chen (李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and Epidemiology, CDER, US FDA
15:20-15:40	Lectures - Overview of Communication mechanisms: Industry Aspects	Wimolsiri Punjatanasak Regulatory Affairs Director, MSD (Thailand) Ltd., RA-EWG APAC (Thailand)
15:40-16:35	Group Discussion	【Moderator】 Min Chen(李敏珠顧問) Principal of US Pharmacovigilance LLC, and Consultant, Division of Medicinal Products, TFDA, and Former Acting Director of
16:35-17:30	Group Presentation	Division of Pharmacovigilance, Office of Surveillance and Epidemiology, CDER, US FDA Wimolsiri Punjatanasak Regulatory Affairs Director, MSD (Thailand) Ltd., RA-EWG APAC (Thailand) [Facilitator] IRPMA&TFDA/CDE Members

September 8 th 2023			
Time	Topics	Affiliation/Economy	
Session 7: Critical thinking and regulatory decision-making 【Moderator】Jo-Feng Chi (祁若鳳研究員), Researcher, Division of Medicinal Product, TFDA			
09:00-09:30	Lectures - The Elements of Quality Regulatory Decision Making	Lawrence Liberti Director, The D. K. Kim International Center for Regulatory Science, University of Southern California (USC)	
09:30-09:50	Lectures - Bridging Study Evaluation (How to accept foreign data): An Overview	Chi-Hsun Chen (陳紀勳醫師) Senior Clinical Section Chief, Center for Drug Evaluation	
09:50-10:05	COFFEE	BREAK	
10:05-11:00	Case Studies (1/2)	【Moderator】 Chi-Hsun Chen(陳紀勳醫師) Senior Clinical Section Chief, Center for Drug Evaluation Wei-Lun Peng(彭偉倫醫師) Senior Medical Reviewer, Division of New Drugs, Center	
11:00-12:00	Case Studies (2/2)	for Drug Evaluation Yi-Lin, Wang (王藝琳資深審查員) Senior Reviewer, Division of Pharmaceutical Science, Center for Drug Evaluation 【Facilitator】 IRPMA&TFDA/CDE Members	

12:00-13:00	LUNCH	
Keynote Speech 3 【Moderator】Hwei-Fang Cheng(陳惠芳副署長), Deputy Director General, TFDA		
13:00-13:40 13:40-13:50	Modernizing Clinical Trials: A Focus on Decentralized Clinical Trials Q&A	M. Khair ElZarrad Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. FDA
14:00-14:30	Closing Remarks Certificate Award Ceremony Closing Remarks	Shou-Mei Wu (吳秀梅署長) Director General, TFDA

三、研討會照片



大合照





丹麥藥品管理局首席醫療官 Dr. Aaron Sosa Mejia 受邀演講





馬來西亞及印尼審查人員分享該國藥品審查經驗





審查案例分組討論





美 FDA 醫藥政策辦公室主任 Dr. M. Khair ElZarrad 受邀視訊演講





吳秀梅署長頒發學員與會證書





吳秀梅署長頒發紀念品予 PMDA 亞洲訓練中心辦公室主任 Ayumi Endo 及 APAC 專家工作組主席 Shinji Hatakeyama

四、 研討會學員回饋

學員對於本次研討會的各項課程評分皆高於4分,對於研討會整體的滿意 度評分達4.5分(表1),顯示學員對於本次研討會辦理十分滿意。此外會前、會 後測驗結果亦顯示學員們於課後對議題之認知皆有顯著提升,學員回饋意見將 作為未來研討會辦理之參考,摘要學員回饋意見於表2、表3。

表 1:研討會整體滿意度

研討會整體滿意度	學員平均滿意度
此次研討會課程是否有增進您對 GRM 理念的認知?	4.5/ 5.0
本次研討會課程是否有達到您的期望?	4.5/ 5.0
研討會整體評價	4.5/ 5.0

表 2:學員認為本次研討會最有幫助的課程

學員認為本次研討會最有幫助的課程

- 新藥申請規劃(Planning of Application: New Drugs)
- 審查人員能力架構(Regulatory competency Framework)
- 銜接性試驗評估(Bridging Study Evaluation)
- 優良送審規範(Good submission practice)
- 查驗登記管理溝通機制(communication)

表 3:學員建議未來研討會之課題

建議未來研討會之課題

- 孤兒藥(Orphan drugs)及罕見疾病治療(Rare disease therapeutic area)相關議題
- 腫瘤藥品之新藥送審規劃(NDA submission of oncology)
- 真實世界證據之趨勢(RWE trend)
- 細胞/基因治療之相關藥品法規(Regulation for cell/gene therapy)
- 數位轉型應用於實踐 GRM 之要件 (Utilizing digital transformation to apply elements of good registration management)